SMMT – summit therapeutics inc. (US:NASDAQ)
Stock Stats
News
Summit Therapeutics (NASDAQ:SMMT) was upgraded by analysts at Barclays PLC from an "underweight" rating to an "equal weight" rating. They now have a $18.00 price target on the stock.
Summit Therapeutics (NASDAQ:SMMT) was given a new $18.00 price target on by analysts at Summit Redstone.
Citi Asserts Buy Rating on Summit Therapeutics Inc. (SMMT) on Pipeline Development [Yahoo! Finance]
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Summit Therapeutics Inc. (SMMT) Presents at Evercore 8th Annual Healthcare Conference Transcript [Seeking Alpha]
Form 8-K Summit Therapeutics Inc. For: Nov 07
Form S-3ASR Summit Therapeutics Inc.
Form 4 Summit Therapeutics Inc. For: Oct 21 Filed by: Xia Yu
Form 4 Summit Therapeutics Inc. For: Oct 21 Filed by: Anand Bhaskar
Form 4 Summit Therapeutics Inc. For: Oct 21 Filed by: Soni Manmeet Singh
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.